The cost-effectiveness of hypertension treatment in Sweden: An analysis of the criteria for intervention and the choice of drug treatment

Journal of Human Hypertension

Volumn 10, Issue SUPPL. 2, 1996, Pages

  Johannesson, Magnus ^a  

^a STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Cost effectiveness; Drugs; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; AGE; AGED; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE; CONFERENCE PAPER; CORONARY RISK; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG CONTRAINDICATION; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MALE; SEX DIFFERENCE; SWEDEN;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; HYPERTENSION; LIFE EXPECTANCY; MALE; MIDDLE AGED; MODELS, ECONOMIC; SWEDEN;

EID: 0029937680     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (13)

1. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977 ; 296 : 732-739.
2. Edelson JT, Weinstein MC, Tosteson AN. et al. Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA 1990 ; 263 : 407-413.
3. Johannesson M. The cost effectiveness of hypertension treatment in Sweden. PharmacoEconomics 1995 ; 7 : 242-250.
4. Johannesson M. The cost-effectiveness of the switch towards more expensive antihypertensive drugs. Health Policy 1994 ; 28 : 1-13.
5. Johannesson M, Jönsson B. Cost-effectiveness analysis of hypertension treatment: a review of methodological issues. Health Policy 1991 ; 19 : 55-78.
6. Johannesson M, Hedbrant J, Jönsson B. A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Med Inform 1991 ; 16 : 355-362.
7. Kannel WB, Wolf PA, Garrison RJ (eds). The Framingham study: an epidemiological investigation of cardiovascular disease, section 37, the probability of developing certain cardiovascular diseases in eight years at specified values of some characteristics. Springfield: U.S. Department of Commerce, National Technical Information Service, 1987.
8. Nilsson P, Andersson DKG, Andersson P-E, et al. Cardiovascular risk factors in treated hypertensives : a nationwide, cross-sectional study in Sweden J Int Med 1993 ; 233 : 239-245.
9. Hebert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Int Med 1993 ; 153 : 578-581.
10. Johannesson M, Borgquist L, Jönsson B. The costs of treating hypertension in Sweden: an empirical investigation in primary health care. Scand J Prim Health Care 1991 ; 9 : 155-160.
11. Nilsson P, Kandell-Collén A, Lindholm LH, et al. Care of hypertensives in Dalby: organization and health economic aspects. J Human Hypertens 1993 ; 7 : 551-554.
12. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part 2, short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990 ; 335 : 827-838.
13. Tosteson AN, Rosenthal DI, Melton LJ, Weinstein MC. Cost-effectiveness of screening perimenopausal white women for osteoporosis : bone densitometry and hormone replacement therapy. Ann int Med 1990 ; 113 : 594-603.